Hikma Pharmaceuticals PLC
Hikma Pharmaceuticals PLC (HKMPY) Stock Overview
Explore Hikma Pharmaceuticals PLC’s financial performance, market position, analyst ratings, and future outlook.
Key Financials
Key Financials
Market Cap
6.1B
P/E Ratio
16.96
EPS (TTM)
$3.22
ROE
0.16%
HKMPY Stock Analysis & Investment Overview
Our comprehensive AI-powered analysis of Hikma Pharmaceuticals PLC (HKMPY) provides investors with deep insights into the stock's performance, growth potential, and market positioning. With a Meyka AI Score of B+, this stock demonstrates moderate investment characteristics based on our advanced machine learning models.
The current technical analysis reveals key indicators including an RSI of 53.90, suggesting the stock is in a neutral condition. Our forecasting models predict significant price movements, with a 12-month target of $58.24.
Key financial metrics showcase the company's fundamental strength, including a P/E ratio of 16.96 and a market capitalization of 6.1B. These metrics, combined with our AI analysis, provide a comprehensive view for both institutional and retail investors.